New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 26, 2013
04:55 EDTALKS, ALKS, ANGO, ANGO, SNSS, SNSS, VHS, VHS, IART, IART, OCR, OCR, BKD, BKD, BAX, BAX, ARIA, ARIARBC Capital to host a conference
Healthcare Conference is being held in New York on February 26-27.
News For ALKS;ANGO;SNSS;VHS;IART;OCR;BKD;BAX;ARIA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
December 11, 2014
06:14 EDTARIAARIAD downgraded to Underperform from Neutral at Credit Suisse
Subscribe for More Information
December 10, 2014
17:19 EDTBAXBaxter announces filing of Form 10 in connection with planned spin-off
Subscribe for More Information
10:00 EDTSNSSOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:23 EDTSNSSOn The Fly: Pre-market Movers
Subscribe for More Information
06:40 EDTSNSSSunesis upgraded to Buy from Hold at Cantor
Subscribe for More Information
December 9, 2014
12:22 EDTBAXPiper Jaffray biopharm analyst holds an analyst/industry conference call
Senior Research Analyst Schimmer, along with Biopharmaceuticals Analyst Breazzano, discuss gene therapy for hemophilia on an Analyst/Industry conference call to be held on December 11 at 10 am.
09:10 EDTARIAARIAD takeover rumors rekindled, Independent says
Subscribe for More Information
07:44 EDTOCROmnicare management to meet with UBS
Meeting to be held in San Francisco on December 9 hosted by UBS.
07:37 EDTARIAARIAD announces safety, efficacy follow-up data on Iclusig
Subscribe for More Information
07:36 EDTARIAARIAD says Iclusig shows anti-leukemic activity in long-term follow up data
ARIAD Pharmaceuticals announced long-term follow up data from the Phase 1 trial of Iclusig, its approved BCR-ABL inhibitor, in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia. The study now shows that with a median follow-up of four years in chronic phase CML patients, Iclusig continues to demonstrate anti-leukemic activity in patients with limited treatment options and that responses have been maintained in CP-CML patients with 72 percent having a major cytogenetic response, 65 percent having a complete cytogenetic response and 56 percent having a major molecular response. Long-term safety data show that careful benefit-risk evaluations should guide decisions to use and maintain ponatinib therapy, particularly in patients who may be at increased risk for arterial thrombotic events. These data were featured in a poster presentation on December 8 at the 56th Annual Meeting of the American Society of Hematology taking place in San Francisco.
07:29 EDTIARTIntegra LifeSciences shares undervalued, says Oppenheimer
Subscribe for More Information
06:31 EDTANGOAngioDynamics signs agreement with HealthTrust covering PICC products
AngioDynamics announced it signed an agreement with HealthTrust covering PICC products. HealthTrust, which serves nearly 1,400 hospitals, 800 ambulatory surgery centers and members in more than 10,600 other locations, including physician practices, long-term care and alternate care sites, has an annual purchasing volume that exceeds $23B.
December 8, 2014
13:34 EDTSNSSSunesis announces positive results from ongoing trial of Vosaroxin
Subscribe for More Information
12:40 EDTSNSSOn The Fly: Midday Wrap
Subscribe for More Information
09:29 EDTSNSSSunesis risk/reward attractive, says RBC Capital
RBC Capital believes that the EU could approve Sunesis' vosaroxin drug. The firm says that an EU approval would lift the stock by about 35%, and ir keeps a $3 price target and Sector Perform rating on the shares.
08:50 EDTALKSAlkermes price target raised to $63 on pipeline catalysts at Credit Suisse
Subscribe for More Information
07:36 EDTARIAARIAD: Iclusig demonstrates anti-leukemic activity in patents in Phase 2 trial
Subscribe for More Information
05:51 EDTSNSSSunesis to host conference call
Conference call to discuss results from the Phase 3 VALOR trial of vosaroxin and cytarabine will be held on December 9 at 1:30 pm. Webcast Link
December 7, 2014
16:42 EDTSNSSSunesis announces presentation of Phase 3 VALOR trial results
Subscribe for More Information
December 6, 2014
09:15 EDTSNSSSunesis to hold a meeting
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use